Clinical Experience With Intramuscular Clozapine.

Area of Science:

• Psychiatry and Pharmacology
• Schizophrenia Treatment
• Drug Delivery Systems

Background:

• Clozapine is the most effective treatment for treatment-refractory schizophrenia.
• Many patients refuse oral clozapine, limiting treatment options.
• Intramuscular (IM) clozapine offers a potential alternative administration route.

Purpose of the Study:

• To review existing studies on the administration and efficacy of IM clozapine.
• To assess the role of IM clozapine in managing patients who refuse oral formulations.
• To summarize the safety and tolerability profile of IM clozapine.

Main Methods:

• Systematic review of published literature on IM clozapine.
• Analysis of retrospective studies and case reports detailing IM clozapine use.
• Examination of data on dosage, treatment duration, and patient outcomes.

Main Results:

• IM clozapine has been used successfully in patients refusing oral intake, with doses around half of oral equivalents.
• Most patients (60-100%) transitioned successfully to oral clozapine after short-term IM treatment.
• Adverse effects were similar to oral clozapine, with faster onset of sedative and cardiovascular effects; local reactions occurred with long-term use.

Conclusions:

• IM clozapine is a valuable tool for facilitating transition to oral therapy in patients with treatment-refractory schizophrenia who refuse oral administration.
• It effectively addresses clozapine refusal, improving treatment adherence and outcomes.
• Further research, particularly on safety, is needed to fully understand IM clozapine's limitations and optimize its use.